Hyrimoz Shortage: What Providers and Prescribers Need to Know in 2026

If your patients are reporting difficulty filling Hyrimoz (adalimumab-adaz), the problem is real — even though Hyrimoz is not on any official drug shortage list. The adalimumab biosimilar market underwent dramatic changes in 2024–2025, and the downstream effects on patient access are still being felt in 2026. This guide provides a clinical and operational overview for rheumatologists, gastroenterologists, dermatologists, and other prescribers managing patients on Hyrimoz.

Current Availability Status

As of early 2026, Hyrimoz is not on the FDA or ASHP drug shortage lists. Sandoz continues to manufacture and distribute adalimumab-adaz in the United States. However, Sandoz did file discontinuation notices in January 2026 for several specific low-concentration formulations (NDC numbers), citing the availability of equivalent high-concentration citrate-free formats. Clinically, this means some patients on the low-concentration 50 mg/mL formulation may need to be transitioned to the 100 mg/mL citrate-free version — a straightforward switch with no dose adjustment required.

The Formulary Disruption: What Changed and Why

The most significant driver of patient access difficulties is the formulary restructuring that began in April 2024 and continued through 2025. Major PBMs made competing moves:

CVS Caremark (Cordavis): Removed brand-name Humira from preferred formularies (April 2024). Preferred products: Hyrimoz (branded and Cordavis private-label). By August 2024, had converted 97% of commercial Humira patients to biosimilars.

Express Scripts (Quallent): Preferred Cyltezo (adalimumab-adbm) and its private-label version. Hyrimoz may require PA or be non-preferred.

Optum Rx (Nuvaila): Has its own private-label preferred product. Hyrimoz coverage varies by specific plan.

The practical implication: a patient's ability to access Hyrimoz depends entirely on which PBM manages their pharmacy benefit. This creates a fragmented prescribing environment that can be difficult to navigate without benefit verification prior to prescribing.

Interchangeability: Clinical and Regulatory Update

As of 2026, Hyrimoz has FDA interchangeable designation across all relevant strengths. Seven adalimumab biosimilars now carry interchangeable status: Amjevita, Cyltezo, Hadlima, Hyrimoz, Hulio, Simlandi, and Yuflyma.

From a clinical standpoint, switching between interchangeable adalimumab biosimilars is supported by evidence. The NOR-SWITCH trial demonstrated no significant difference in efficacy, safety, or immunogenicity when switching from the reference product to a biosimilar. Multiple real-world studies have since confirmed these findings for switches between biosimilars. Patients stable on Hyrimoz can be safely transitioned to another interchangeable biosimilar if formulary or availability requires it, with appropriate monitoring.

Prescribing Considerations for 2026

When starting or managing patients on adalimumab therapy, consider these practice points:

Verify formulary before prescribing: Your patient's PBM determines which biosimilar is preferred. Ask patients (or your benefits coordinator) to confirm which adalimumab product is covered under their plan.

Prescribe generically when appropriate: Prescribing "adalimumab" gives the pharmacy and insurance flexibility to dispense the formulary-preferred biosimilar. For new starts, this can reduce PA delays.

Specify formulation when clinically important: For pediatric patients, patients with injection site reactions to citrate-containing formulations, or specific dosing requirements, specifying the formulation (e.g., high-concentration citrate-free) can prevent dispensing errors.

Monitor for anti-drug antibodies (ADA): When switching between adalimumab products, immunogenicity monitoring is generally not required by evidence, but patients with a history of ADA development should be monitored closely for efficacy.

Pre-authorize early: For established patients, submit prior authorization renewals at least 60 days before expiration to avoid treatment gaps.

Patient Populations Requiring Special Attention

Certain patient populations need extra care during the current formulary transition period:

Pediatric patients: Not all biosimilars are approved for children for all indications. Hyrimoz is approved for JIA (age 2+), CD (age 6+), and uveitis (age 2+). Confirm pediatric approval before substituting.

Patients in remission: Patients who achieved remission on adalimumab may be appropriately anxious about switching. Clinical data supports switching, but shared decision-making and reassurance are important.

Medicare patients: Manufacturer co-pay programs (including Sandoz One Source) are not available for Medicare patients. These patients may have higher out-of-pocket costs, especially if they haven't met their Part D deductible.

Resources to Help Your Patients Access Hyrimoz

Sandoz One Source: 1-833-497-4669 | hyrimoz.com. Covers benefits investigation, PA support, specialty pharmacy enrollment, and copay card enrollment for eligible commercially insured patients.

CoverMyMeds: Electronic PA platform integrated with most EHRs. Sandoz supports CoverMyMeds for Hyrimoz PA submissions.

medfinder: Real-time pharmacy availability data. Visit medfinder.com/providers to learn how medfinder helps provider offices locate specialty drugs for patients.

Looking Ahead

The adalimumab market will continue to mature in 2026 and beyond. Pricing pressure from 10+ biosimilar competitors should benefit patients over time, and formulary consolidation will reduce — but not eliminate — navigation complexity. For a step-by-step guide to helping your patients find Hyrimoz, see our provider's guide to helping patients find Hyrimoz in stock.